Neoolife includes an international, multidisciplinary team with more than 130 years of cumulative experience in biomedical technology and device therapy. Our business team has a recognized track of leadership in both large corporations and start-ups.
Our worldwide recognized bio/chemical/mechanical engineers and cardiovascular physicians have a long-lasting involvement in the research & development, clinical, and academic fields of cardiovascular disease.
Neoolife is also developing unique solutions for the percutaneous treatment of heart valve disease, i.e., tricuspid valve regurgitation.
We focus on tissue-engineered Biomimetic Heart Valves (BMHV) and tissue-engineered Biomimetic Cardiovascular Patches (BMCP) that enable endogenous in situ tissue regeneration. Our technology is used for percutaneous and surgical applications.
Neoolife polymeric tissue-engineered biomimetic products are durable, non-thrombogenic, and resistant to calcification.